TLC-ART Program

“We hope to maximally suppress HIV and potentially contribute to a cure for AIDS.” Dr. Rodney Ho

Targeted Long Acting Therapy intended to clear virus in tissues

We are the Targeted Long-acting Combination Anti-Retroviral Therapy (TLC-ART) program, located within the Department of Pharmaceutics at the University of Washington.  We are scientists and physicians working toward developing a long acting and effective treatment to improve patient compliance and therapeutic outcomes in the treatment of HIV. Our hope is to maximally suppress HIV and potentially contribute to a cure for AIDS.

School of Pharmacy School of Medicine Institute for Translational Health Sciences Seattle Children's Harborview Fred Hutch Center for AIDS Research

Our researchers were the first to document pharmacological drug deficiency with HIV oral treatment. This has been linked to residual HIV in tissues. The TLC-ART program, with its 11 projects, intends to overcome pharmacological drug deficiency by developing a novel formulation of a combination of antiretroviral agents. TLC-ART is a publicly funded, National Institutes of Health (NIH) supported program with contributions from multiple institutions.

We welcome your input, research support, participation and donations by either making a gift or donating directly to our faculty or students.